Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Liabilities and Shareholders Equity (2022 - 2025)

Coya Therapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $32.0 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 9.87% year-over-year to $32.0 million; the TTM value through Sep 2025 reached $148.2 million, down 3.83%, while the annual FY2024 figure was $44.3 million, 7.48% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $32.0 million at Coya Therapeutics, down from $33.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $44.3 million in Q4 2024 and bottomed at $8.4 million in Q4 2022.
  • The 4-year median for Liabilities and Shareholders Equity is $34.5 million (2024), against an average of $29.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 391.48% in 2023 before it dropped 16.24% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $8.4 million in 2022, then skyrocketed by 391.48% to $41.3 million in 2023, then grew by 7.48% to $44.3 million in 2024, then dropped by 27.75% to $32.0 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Liabilities and Shareholders Equity are $32.0 million (Q3 2025), $33.5 million (Q2 2025), and $38.4 million (Q1 2025).